Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: CHIP-seq data of Project identifying SNRPC as a regulator for facilitating triple-negative breast cancer progression

PROVIDER: PRJNA931800 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23345541.fastq.gz	Fastqsanger.gz
	SRR23345541_1.fastq.gz	Fastqsanger.gz
	SRR23345541_2.fastq.gz	Fastqsanger.gz
	SRR23345542.fastq.gz	Fastqsanger.gz
	SRR23345542_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 162

Similar Datasets

In vivo CRISPR screen identifies SNRPC as a regulator for facilitating triple-negative breast cancer progression

Project description:In vivo CRISPR screen identifies SNRPC as a regulator for facilitating triple-negative breast cancer progression

| PRJNA943537 | ENA

Project description:In vivo CRISPR screen identifies SNRPC as a regulator for facilitating triple-negative breast cancer progression

| PRJNA922615 | ENA

Project description:RBP-CRISPR data of "In vivo CRISPR screen identifies SNRPC as a regulator for facilitating triple-negative breast cancer progression"

| PRJNA943113 | ENA

Project description:RBP-CRISPR Plasmid data of "In vivo CRISPR screen identifies SNRPC as a regulator for facilitating triple-negative breast cancer progression"

| PRJNA944405 | ENA

Project description:SNRPC promotes triple negative breast cancer progression partially by enhancing TNFAIP2 expression

| PRJNA888951 | ENA

Homo sapiens

Project description:HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

| PRJNA194135 | ENA

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Project description:Triple negative breast cancer is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study was to explore the clinical relevance of Lehmann triple negative breast cancer subtypes by identifying any differences in response to neoadjuvant chemotherapy among them.

2017-11-17 | GSE106977 | GEO

HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

Project description:Emerging evidence suggests that tumor cells metastasize by co-opting stem cell transcriptional networks, although the molecular underpinnings of this process are poorly understood. Here, we show for the first time that the high mobility group A1 (HMGA1) gene drives metastatic progression in triple negative breast cancer cells (MDA-MB-231) by reprogramming cancer cells to a stem-like state. We discovered an HMGA1 signature in triple negative breast cancer cells that is highly enriched in embryonic stem cells. Together, these findings indicate that HMGA1 is a master regulator of tumor progression in breast cancer by reprogramming cancer cells through stem cell transcriptional networks. Future studies are needed to determine how to target HMGA1 in therapy.

2015-02-18 | GSE45483 | GEO

SIPA1 Functions as a Transcription Regulator to Sustain Progression of Triple-Negative Breast Cancer

Project description:SIPA1 Functions as a Transcription Regulator to Sustain Progression of Triple-Negative Breast Cancer

| PRJNA915946 | ENA

HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

2015-02-18 | E-GEOD-45483 | biostudies-arrayexpress